ReviewCardiology research and practice2021
Cardiac Injury Biomarkers and the Risk of Death in Patients with COVID-19: A Systematic Review and Meta-Analysis.
Review in Cardiology research and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Cardiac Injury in COVID-19: A Systematic Review of Relevant Meta-Analyses.Reviews in cardiovascular medicine · 2022Pooled it
- Forecasting readmission in COVID-19 patients utilizing blood biomarkers and machine learning in the Hospital-at-Home program.Frontiers in medicine · 2025Article
- Prevalence of early bacterial co-infection in hospitalized patients with COVID-19 pneumonia: a retrospective study.Journal of thoracic disease · 2023Article
- Predictive value of cord blood myocardial enzyme and troponin levels for myocardial injury after neonatal asphyxia.American journal of translational research · 2023Article
- Myocardial Injury and Prognosis in Hospitalized COVID-19 Patients in Brazil: Results From The Brazilian COVID-19 Registry.Arquivos brasileiros de cardiologia · 2023Article
- The coronavirus disease-19 pandemic and acute coronary syndrome: a specific impact in the elderly.Journal of geriatric cardiology : JGC · 2022Article
- COVID19 biomarkers: What did we learn from systematic reviews?Frontiers in cellular and infection microbiology · 2022Review
- Demographic, clinical, electrocardiographic and echocardiographic characteristics of patients hospitalized with COVID-19 and cardiac disease at a tertiary hospital, South Africa.Cardiovascular diagnosis and therapy · 2021Article
- High-value laboratory testing for hospitalized COVID-19 patients: a review.Future virology · 2021Review
- Specific Risk Factors for Fatal Outcome in Critically Ill COVID-19 Patients: Results from a European Multicenter Study.Journal of clinical medicine · 2021Article
- Global burden of acute myocardial injury associated with COVID-19: A systematic review, meta-analysis, and meta-regression.Annals of medicine and surgery (2012) · 2021Review
- Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac complications may develop in a proportion of patients with the novel coronavirus disease (COVID-19), which may influence their prognosis.
objectivesTo assess the role of cardiac injury biomarkers measured on admission and during hospitalization as risk factors for subsequent death in COVID-19 patients.
methodsA systematic review and meta-analysis was carried out involving cohort studies that compared the levels of cardiac injury biomarkers in surviving and dead COVID-19 patients. Cardiac injury is defined as an elevation of the definitive markers (cardiac troponin (cTnI and cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP)) above the 99th percentile upper reference limit. Secondary markers included creatine kinase-myocardial bound (CK-MB), myoglobin, interleukin-6 (IL-6), and C-reactive protein (CRP). The risk of death and the differences in marker concentrations were analyzed using risk ratios (RRs) and standardized mean differences (SMDs), respectively.
resultsNine studies met the inclusion criteria (1799 patients, 53.36% males, 20.62% with cardiac injury). The risk of death was significantly higher in patients with elevated cTn than those with normal biomarker levels (RR = 5.28,
conclusionCOVID-19 patients with elevated cTn on admission, possibly due to immune-mediated myocardial injury, are at increased risk for mortality. This requires further radiographic investigations, close monitoring, and aggressive care to reduce the risk of severe complications and death.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.